Innate Pharma (ADR) (IPHA)
Develops innate-immunity-based antibody therapies for cancer alongside AstraZeneca and Sanofi collaborations.
Something off on this page? Send us feedback.
Develops antibody-based cancer therapies through monoclonal antibodies, ANKET NK-cell engagers, and ADCs. Its lead assets include lacutamab, IPH4502, and AstraZeneca-partnered monalizumab, while collaborations with Sanofi and AstraZeneca shape clinical development.
Develops antibody-based cancer therapies rooted in innate-immune biology and natural-killer-cell engagement. Its clinical portfolio spans monoclonal antibodies, ANKET multispecific NK-cell engagers, and antibody-drug conjugates, following an earlier anti-KIR focus.
Lacutamab, IPH4502, and AstraZeneca-partnered monalizumab are the cited lead assets. Clinical programs cover T-cell lymphomas, solid tumors, and non-small-cell lung cancer; Sanofi and AstraZeneca collaborations form a core part of the development model.
Operations are based in Marseille, with a U.S. office in Rockville, Maryland. The business depends on advancing ongoing proprietary clinical programs and partner-led development, licensing, and commercialization arrangements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 12, 2026 | BTIG | Reiterate | Rating: —Target: — | Target: $9 |
| Aug 11, 2026 | Citigroup | Upgrade | ||
| Aug 11, 2026 | Leerink Partners | Target | Target: $2 | Target: $4 |
| Aug 10, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $5 | Target: $7 |
| Oct 29, 2025 | H.C. Wainwright | Target | Target: — | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.4M · Total debt $23.0M · Total assets $39.6M · Shareholders' equity −$46.1M
- Revenue
- $3.6M
- Operating income
- −$24.9M
- Net income
- −$22.7M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 0.20% | 192.4K ADS | |
|---|---|---|---|
| 10 holders · as of Jun 30, 2026 | |||
| Insiders | 16.68% | 15.66M ADS | |
| 2 holders · as of May 7, 2025 | |||
| Other | 83.12% | 78.05M ADS | |
| remainder | |||
93.90M ADS as of Sep 7, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
SanofiInsider | 8.89% | 8.35M | filed Apr 29, 2025 |
Caisse des depots et consignationsInsider | 7.79% | 7.32M | filed May 7, 2025 |
Lion Point Capital, LPInstitution | 0.09% | 81,151 ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.05% | 43,524 ADS | as of Jun 30, 2026 |
Smartharvest Portfolios, LLCInstitution | 0.03% | 23,750 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Pfizer
Commercial Nectin-4 ADC franchise through PADCEV
- Eli Lilly
Phase 1 Nectin-4 ADC development in solid tumors
- Corbus Pharmaceuticals
Clinical Nectin-4 ADC developer in advanced solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Innate Pharma (ADR) | $1.80 | 0.00% | $169.0M | — | — | 136.6 | +12.9% |
| Pfizer | $28.01 | +0.27% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Eli Lilly | $1,155.26 | −1.27% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Corbus Pharmaceuticals | $7.89 | +0.13% | $145.9M | — | — | — | — |
| Median | 38.1 | 19.1 | 8.2 | +25.1% |